FIELD: chemistry.
SUBSTANCE: present invention relates to novel compounds of the general formula (I) given below, physiologically acceptable salts of compounds of formula (I), where R3 denotes a hydrogen atom, as well as geometric isomers of compounds of formula (I), having RAR receptor (α, β, γ) inhibitory activity, use thereof to obtain pharmaceutical compositions and pharmaceutical compositions based on said compounds 
In formula (I), R1 denotes a hydrogen atom, an alkyl radical having 1-4 carbon atoms, or a CF3 radical; R2 denotes a hydrogen atom; R3 denotes a hydrogen atom or a straight alkyl or a radical having 1-10 carbon atoms; R4 and R5 denote a hydrogen atom or an alkyl radical having 1-3 carbon atoms, or alternatively, R4 and R5 denote a pyrrolidine ring, Y denotes two hydrogen atoms or an oxygen atom; Ar denotes a 1,4-phenyl ring; X denotes an oxygen or a single C-C bond, and A assumes values given in the claim.
EFFECT: obtaining novel compounds.
15 cl, 3 dwg, 56 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZABENZOFURANYL COMPOUNDS AND METHODS OF USE | 2007 |
|
RU2448111C2 |
| PAN-GENOMIC INHIBITORS OF THE HEPATITIS C VIRUS PROTEIN NS5A, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR THE SYNTHESIS OF INHIBITORS, AND METHODS FOR THEIR PREPARATION AND USE | 2016 |
|
RU2669919C1 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| NEW β-LACTAMASE INHIBITOR AND A METHOD OF ITS PRODUCTION | 2019 |
|
RU2800050C2 |
| NOVEL BETA-LACTAMASE INHIBITOR AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2693898C2 |
| SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | 2006 |
|
RU2422446C2 |
| METHOD OF PRODUCING A DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | 2014 |
|
RU2719480C2 |
| N, N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS EFFECTIVE AS MONOAMINE REABSORPTION INHIBITORS | 2006 |
|
RU2414454C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
